Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.68 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452347 | 0.86 | KDM4E (0.70) | HSP90AA1HSP90AB1KDM4EMEN1MAPT | |
| SCHEMBL3951575 | 0.85 | HSP90AB1 (0.72) | HSP90AA1HSP90AB1KDM4EMEN1MAPT | |
| SCHEMBL14413753 | 0.85 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1KDM4EMEN1MAPT | |
| SCHEMBL908398 | 0.82 | MEN1 (0.52) | HSP90AA1HSP90AB1KDM4EMEN1MAPT | |
| SCHEMBL13288410 | 0.81 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1KDM4EMAPTALDH1A1 | |
| SCHEMBL3451558 | 0.81 | HSP90AB1 (0.68) | HSP90AA1HSP90AB1KDM4EMEN1MAPT | |
| SCHEMBL1643108 | 0.81 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KDM4EMEN1MAPT | |
| SCHEMBL5511069 | 0.81 | KDM4E (0.64) | HSP90AA1HSP90AB1KDM4EMAPTALDH1A1 | |
| SCHEMBL1643582 | 0.81 | KDM4E (0.62) | HSP90AA1HSP90AB1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL717689 | 0.79 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | claimed |
| EP-2049497-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | claimed |
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006123165-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-11-23 | — | — | WO | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4433485-A1 | ADENOSINE RECEPTOR ANTAGONISTS | Crossignal Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | CROSSIGNAL THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-118317965-A | Adenosine receptor antagonists | 交信医药研发公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023091604-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| EP-1562935-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005035507-A2 | 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| US-6815447-B2 | 6-N-(2-AMINO-PYRIMIDIN-4-YL)QUINOLINE-6-AMINE DERIVATIVES; ANALGESICS | ASTRAZENECA AB (SE) | 2004-11-09 | — | — | US | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CHAUDHARI BIPINCHANDRA (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1339706-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036586-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | HSP90AA1 3866/4885HSP90AB1 3432/4885KDM4E 3484/4885 |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | HSP90AA1 2054/4885HSP90AB1 2055/4885KDM4E 4163/4885 |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | HSP90AA1 1760/4885HSP90AB1 2045/4885KDM4E 4625/4885 |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | HSP90AA1 1760/4885HSP90AB1 2045/4885KDM4E 4625/4885 |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | HSP90AA1 3114/4885HSP90AB1 2932/4885KDM4E 4744/4885 |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885KDM4E 4124/4885 |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | ADORA2A, ADORA1, P2RX5 | HSP90AA1 3908/4885HSP90AB1 4318/4885KDM4E 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.